ANCA Vasculitis Drug Market to Surpass US$ 711.83 Mn by 2030

Global ANCA Vasculitis Drug Market, by Type (Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), and Renal-limited Vasculitis), by Drug Type (Glucocorticoids, Cyclophosphamide, Rituximab, Methotrexate, Mycophenolate mofetil, Azathioprine, Mepolizumab, Avacopan, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies  ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 463.82 Million in 2022 and is expected to exhibit a CAGR of 5.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing research and development activities by the researchers to develop more effective treatment options for the treatment of ANCA vasculitis is expected to drive the market growth over the forecast period. For instance, in February 2021, the researchers from the University of Pennsylvania, U.S., showed that the phase 3 clinical trial of avacopan was more effective than glucocorticoids (“steroids” such as prednisone) in keeping patients with ANCA-associated vasculitis, a disease that causes the destructions of the body’s small blood vessels, in remission for a year

Global ANCA Vasculitis Drug Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

The COVID-19 pandemic had a negative economic impact on the global ANCA vasculitis drug market, owing to the decrease in diagnosis rate of ANCA vasculitis. Moreover, patients with ANCA-associated vasculitis have a higher likelihood of developing severe COVID-19, owing to the immunosuppression associated with drugs such as rituximab used in the treatment of ANCA vasculitis. Other immunosuppressive measures commonly used, which include glucocorticoids, anti-metabolites, and potentially cyclophosphamide, impair the humoral and cellular immune response following COVID-19 vaccination. Thus the COVID-19 pandemic had a negative impact on market.

Browse 41 Market Data Tables and 43 Figures spread through 176 Pages and in-depth TOC on “Global ANCA Vasculitis Drug Market”-  Forecast to 2030, Global ANCA Vasculitis Drug Market, by Type (Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), and Renal-limited Vasculitis), by Drug Type (Glucocorticoids, Cyclophosphamide, Rituximab, Methotrexate, Mycophenolate mofetil, Azathioprine, Mepolizumab, Avacopan, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global ANCA Vasculitis Drug Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anca-vasculitis-drug-market-5154

Moreover, positive results of the drugs in clinical trials for the treatment of ANCA vasculitis is expected to drive the market growth over the forecast period. For instance, in November 2019, the phase 3 clinical trial studying avacopan, a first-in-class orally-administered selective complement 5a receptor (C5aR) inhibitor for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis), met its primary endpoints and showed study positive results. The study was carried out by ChemoCentryx, Inc., a clinical stage biopharmaceutical company.

Key Takeaways of the Global ANCA Vasculitis Drug Market:

• Global ANCA vasculitis drug market is expected to exhibit a CAGR of 5.5% during the forecast period due to high number of drug candidates in the pipeline for studying their safety and efficacy for treatment of ANCA vasculitis. For instance, Staidson (Beijing) Biopharmaceuticals Co., Ltd., a China-based company, is studying the efficacy and safety of BDB-001 injection in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The drug candidate is currently in Phase 2 of its clinical trial and the study is estimated to be completed by September 2023
• On the basis of drug type, the glucocorticoids segment is estimated to dominate the market growth in 2022, as glucocorticoids are the first line treatment to rapidly control inflammation and prevent further organ damage in patients with active ANCA-associated vasculitides (AAV)
• Among distribution channels, the hospital segment is expected to dominate market over the forecast period, owing to the increased rate of hospitalizations associated with the ANCA-associated vasculitides (AAV). For instance, according to an article published by the Springer Nature in July 2020, the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy (about 1,200,000 inhabitants) and clinical electronic chart records from the hospital were used as the source of information for the retrospective cohort study to characterize the economic burden of AAV in Friuli Venezia Giulia (FVG), Italy. According to the results, between the years 2013 and 2018, 103 patients with diagnostic code for ANCA-associated vasculitides (AAV) were identified in FVG, of which the whole number of hospitalizations was 285 in 74 patients (rate of 57 events per year), with an inpatient prevalence of 23.2 cases per 100 000 admissions. Fifty-five out of 74 (74.3%) patients experienced more than one hospitalization.
• Major players operating in the global ANCA vasculitis drug market include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca